Apolipoprotein C-III in patients with systemic lupus erythematosus.
Apolipoprotein C3
Systemic lupus erythematosus
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
10 05 2022
10 05 2022
Historique:
received:
22
09
2021
accepted:
01
05
2022
entrez:
10
5
2022
pubmed:
11
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
Systemic lupus erythematosus (SLE) has been associated with atherosclerotic cardiovascular disease (CV) and an altered lipid profile. High levels of apolipoprotein C-III (ApoC3) are associated with elevated triglyceride levels and an increased risk of CV. In the present study, we aimed to study circulating ApoC3 in patients with SLE and describe its relationship with the manifestations of the disease. This is a cross-sectional study that included 186 patients with SLE. Disease-related data, CV comorbidity, full lipid profile, and serum levels of ApoC3 were assessed. A multivariable regression analysis was performed to study how ApoC3 was related to SLE features. Classic CV risk factors were significantly and strongly associated with circulating ApoC3. After a fully multivariable analysis that included classic CV risk factors and lipid profile molecules, SLICC damage (beta coef. 0.10 [95% CI 0.02-0.19] mg/dl, 0.020) and Katz severity (beta coef. 0.11 [95% CI 0.03-0.19] mg/dl, p = 0.011) indices and SLEDAI activity score (beta coef. 0.05 [95% CI 0.05-0.08] mg/dl, p = 0.004) were all independently associated with higher levels of circulating ApoC3. Among SLE patients, disease activity, severity, and disease damage are independently associated with higher ApoC3 serum levels.
Sections du résumé
BACKGROUND
Systemic lupus erythematosus (SLE) has been associated with atherosclerotic cardiovascular disease (CV) and an altered lipid profile. High levels of apolipoprotein C-III (ApoC3) are associated with elevated triglyceride levels and an increased risk of CV. In the present study, we aimed to study circulating ApoC3 in patients with SLE and describe its relationship with the manifestations of the disease.
METHODS
This is a cross-sectional study that included 186 patients with SLE. Disease-related data, CV comorbidity, full lipid profile, and serum levels of ApoC3 were assessed. A multivariable regression analysis was performed to study how ApoC3 was related to SLE features.
RESULTS
Classic CV risk factors were significantly and strongly associated with circulating ApoC3. After a fully multivariable analysis that included classic CV risk factors and lipid profile molecules, SLICC damage (beta coef. 0.10 [95% CI 0.02-0.19] mg/dl, 0.020) and Katz severity (beta coef. 0.11 [95% CI 0.03-0.19] mg/dl, p = 0.011) indices and SLEDAI activity score (beta coef. 0.05 [95% CI 0.05-0.08] mg/dl, p = 0.004) were all independently associated with higher levels of circulating ApoC3.
CONCLUSION
Among SLE patients, disease activity, severity, and disease damage are independently associated with higher ApoC3 serum levels.
Identifiants
pubmed: 35538496
doi: 10.1186/s13075-022-02793-y
pii: 10.1186/s13075-022-02793-y
pmc: PMC9088095
doi:
Substances chimiques
APOC3 protein, human
0
Apolipoprotein C-III
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104Informations de copyright
© 2022. The Author(s).
Références
Int J Womens Dermatol. 2021 Sep 09;7(5Part A):560-575
pubmed: 35024413
Rheumatology (Oxford). 2020 Oct 1;59(10):2847-2856
pubmed: 32065639
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
Free Radic Res. 2007 Dec;41(12):1301-12
pubmed: 17957542
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Ther Adv Musculoskelet Dis. 2020 Nov 28;12:1759720X20975904
pubmed: 33294038
Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-99-104
pubmed: 17083771
Rheumatology (Oxford). 2022 Apr 11;61(4):1408-1416
pubmed: 34240117
J Rheumatol. 2002 Feb;29(2):288-91
pubmed: 11838846
N Engl J Med. 2014 Jul 3;371(1):32-41
pubmed: 24941082
Circulation. 2008 Aug 12;118(7):702-4
pubmed: 18695202
Lupus. 1993 Apr;2(2):119-23
pubmed: 8330033
Arthritis Care Res (Hoboken). 2015 Mar;67(3):442-6
pubmed: 25155365